Bharat, TJU partnering on COVID-19 vaccine

By The Science Advisory Board staff writers

May 20, 2020 -- Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

The vector used in the new COVID-19 vaccine is an existing deactivated rabies vaccine, which was invented at the university. It's being used because it produces a strong immune response and is approved for use in children and adults, including pregnant women.

The vaccine showed a strong antibody response in mice, and researchers are testing whether vaccinated animals are protected from SARS-CoV-2 infection. Results are expected in June. Bharat Biotech aims to get into human trials as soon as December 2020.

Bharat Biotech has exclusive rights to develop, market, and deliver TJU's vaccine across the world, excluding the U.S., Europe, and Japan. The university continues to look for partners in those countries.

Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...
BARDA gives $20M to Sabin Vaccine Institute for vaccines
The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded the Sabin Vaccine Institute $20 million to manufacture and release...
Neovii, Tel Aviv University partner for COVID-19 vaccine
Israeli firm Ramot has inked a license agreement with Neovii, a Swiss-based biopharmaceutical company, for the research and development of a COVID-19...
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter